<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="drugs available on the market to act against SARS-CoV-2 [65â€&quot;67]." exact="Chloroquine" post="and hydroxychloroquine stand as excellent examples and are being"/>
 <result pre="on the market to act against SARS-CoV-2 [65â€&quot;67]. Chloroquine and" exact="hydroxychloroquine" post="stand as excellent examples and are being adopted at"/>
 <result pre="can be considered to relieve pain. The reports for avoiding" exact="ibuprofen" post="are not validated yet [69,70]. These reports suggest that"/>
 <result pre="of SARS-CoV-2 in Washington, USA. The dosage of 650Â mg" exact="acetaminophen" post="everyÂ 4Â h and 600Â mg ibuprofen every 6"/>
 <result pre="of 650Â mg acetaminophen everyÂ 4Â h and 600Â mg" exact="ibuprofen" post="every 6 h was administered as prescribed to the"/>
 <result pre="6Â days of hospitalization, he was also given 600Â mg" exact="guaifenesin" post="for persistent coughing and around 6 L of regular"/>
 <result pre="a combination of antibiotics. Used antibiotics included cephalosporins, quinolones, carbapenems," exact="tigecycline" post="and/or linezolid [75]. Another study on 139 patients has"/>
 <result pre="of antibiotics. Used antibiotics included cephalosporins, quinolones, carbapenems, tigecycline and/or" exact="linezolid" post="[75]. Another study on 139 patients has shown that"/>
 <result pre="The investigations include antiviral drugs such as lopinavir, ritonavir, favipiravir," exact="ribavirin" post="and remdesivir [78]. Investigated drugs also include antimalarials, immunomodulators,"/>
 <result pre="(LPV) is a HIV type 1 aspartate protease inhibitor while" exact="ritonavir" post="(RTV) is usually combined to it to increase the"/>
 <result pre="twice daily; days 2â€&quot;14: 600Â mg twice daily) plus interferon" exact="alpha" post="(IFN-Î±) by aerosol inhalation (5Â million U twice daily)."/>
 <result pre="antiviral regimens. Examples of combinations are LPV/RTV plus FPV, darunavir/ritonavir," exact="chloroquine" post="and FPV combined with tocilizumab [83]. Clinical trials are"/>
 <result pre="to death will be compared with the placebo group [88]." exact="Ribavirin" post="(RBV) is another broad-spectrum antiviral agent and acts as"/>
 <result pre="clinical trial for its potentials against SAR-CoV-2 [95]. Antimalarial agents" exact="Chloroquine" post="(CQ) is currently being investigated extensively for its promising"/>
 <result pre="poisoning risk (rhythm disturbance, QT interval prolongation) [98]. The derivative" exact="hydroxychloroquine" post="(HCQ) was developed later and showed better clinical safety"/>
 <result pre="duration 10 days) [77]. A novel combination of CQ and" exact="azithromycin" post="was used recently in a small French clinical trial"/>
 <result pre="10 days. Out of the HCQ-treated patients, six patients received" exact="azithromycin" post="500Â mg on day 1 and 250Â mg for"/>
 <result pre="in HCQ compared with the control group (70 vs 12.5%)." exact="Azithromycin" post="+ HCQ group showed 100% virological clearance on day"/>
 <result pre="with the sigma receptor. The sigma receptors interact with CQ." exact="Azithromycin" post="has also been shown to be an off-target activity"/>
 <result pre="disease-modifying antirheumatic drug (BoDMARD) and recommended as an alternative to" exact="methotrexate" post="or TNF-Î± antagonists in RA patients [111]. Tocilizumab is"/>
 <result pre="corticosteroids in the recent SARS-CoV-2 outbreak [122]. Corticosteroids such as" exact="methylprednisolone" post="are expected to inhibit inflammatory response that is the"/>
 <result pre="that was diagnosed with SARS-CoV-2, showed that the administration of" exact="methylprednisolone" post="(80Â mg twice daily) to the standard care did"/>
 <result pre="antibiotic (moxifloxacin) and RBV antiviral therapy. Only 12 patients received" exact="methylprednisolone" post="to improve patients' shortness of breath. The study did"/>
 <result pre="study did not indicate any advantages for the use of" exact="methylprednisolone" post="in those patients [28]. Another study was conducted on"/>
 <result pre="IFN-Î±) and nutritional support. Of those, 26 patients additionally received" exact="methylprednisolone" post="at a dose of 12Â mg/kg/d for 5â€&quot;7Â days"/>
 <result pre="supplemental oxygen and better absorption of lung focus [122]. Accordingly," exact="methylprednisolone" post="did not improve mortality outcomes but may result in"/>
 <result pre="trial currently being conducted in China on 48 patients and" exact="methylprednisolone" post="to be administrated to half of them like a"/>
 <result pre="improve the immune response (I4R) approach. Low-level radiation, statins and" exact="aspirin" post="are suggested for the treatment of SARS-CoV-2 pneumonia. This"/>
 <result pre="(ivermectin) Recent in vitro reports demonstrated the potential efficacy of" exact="ivermectin" post="against SAR-COV-2. 5000-fold reduced the viral load (in 2-h"/>
 <result pre="post-infection with SARS-CoV-2 Vero-hSLAM cells) after 48Â h of single" exact="ivermectin" post="treatment (5Â Î¼M) [126]. An observational study showed the"/>
 <result pre="An observational study showed the survival benefits of using single" exact="ivermectin" post="dose (150Â mg/kg) after initiating mechanical ventilation in critically"/>
 <result pre="mechanical ventilation in critically ill SAR-COV-2 patients. Patients who received" exact="ivermectin" post="showed better survival, shorter hospital stay and intensive care"/>
 <result pre="study from Italy is suggesting a synergistic effect of combining" exact="hydroxychloroquine" post="with ivermectin against SAR-COV-2. The study is hypothesizing that"/>
 <result pre="Italy is suggesting a synergistic effect of combining hydroxychloroquine with" exact="ivermectin" post="against SAR-COV-2. The study is hypothesizing that the two"/>
 <result pre="to reduce the symptoms of SARS-CoV-2 infection with baricitinib, and" exact="melatonin" post="being the most related [131]. Baricitinib, a drug approved"/>
 <result pre="Ebola viral infection [134]. As suggested by ChengÂ et al.," exact="melatonin" post="could reduce the clinical symptoms of SARS-CoV-2 infection and"/>
 <result pre="gls-5300 in healthy volunteers. (2020). https://clinicaltrials.gov/ct2/show/study/NCT03721718?term=vaccine&amp;amp;cond=Mers+CoV&amp;amp;draw=2&amp;amp;rank=7 55.Efficacy and safety of" exact="hydroxychloroquine" post="for treatment of pneumonia caused by 2019-ncov (hc-ncov)2020). https://clinicaltrials.gov/ct2/show/NCT04261517"/>
 <result pre="TaoG , ZhangYW , YangGN , HuangPDrug interaction monitoring of" exact="lopinavir" post="/ ritonavir in COVID-19 patients with cancer. Zhonghua Nei"/>
 <result pre="ZhangYW , YangGN , HuangPDrug interaction monitoring of lopinavir /" exact="ritonavir" post="in COVID-19 patients with cancer. Zhonghua Nei Ke Za"/>
 <result pre="infection. (2020). https://clinicaltrials.gov/ct2/results?cond=covid+19&amp;amp;term=Favipiravir+&amp;amp;cntry=&amp;amp;state=&amp;amp;city=&amp;amp;dist= 84.WangM , CaoR , ZhangLet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
 <result pre="91.collab: Clinicaltrials.Gov. An Open-label Randomized Controlled Trial on Lopinavir/ Ritonavir," exact="Ribavirin" post="and Interferon Beta 1b Combination Versus Lopinavir/ Ritonavir Alone,"/>
 <result pre="Lopinavir/ Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/" exact="Ritonavir" post="Alone, as Treatment for 2019 Novel Coronavirus Infection. (2020)."/>
 <result pre="a review. 2020030275 (2020). . 97.GaoJ , TianZ , YangXBreakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
 <result pre="ShabaniM , ShokouhiS , SaffaeiAAminoquinolines Against Coronavirus Disease 2019 (COVID-19):" exact="Chloroquine" post="or Hydroxychloroquine. Int J Antimicrob Agents.105945 (2020).32194152 99.PhilippeGautreta J-CL"/>
 <result pre="(2020).32194152 99.PhilippeGautreta J-CL , PhilippeParolaa , VanThuan Hoanget al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
 <result pre="Vitro Antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
 <result pre="SARS-CoV-2/COVID-19 with nitazoxanide and hydroxychloroquine. 103.collab: Chctr.Org. Clinical Trials on" exact="Chloroquine" post="for SARS-COV-2 infection. (2020). http://www.chictr.org.cn/searchprojen.aspx 104.collab: Clinicaltrials.Gov. Clinical trials"/>
 <result pre="for SARS-COV-2 infection. (2020). http://www.chictr.org.cn/searchprojen.aspx 104.collab: Clinicaltrials.Gov. Clinical trials on" exact="chloroquine" post="(2020). https://clinicaltrials.gov/ct2/results?cond=Covid+19&amp;amp;term=chloroquine&amp;amp;cntry=&amp;amp;state=&amp;amp;city=&amp;amp;dist= 105.collab: Clinicaltrials.Gov. Various Combination of Protease Inhibitors,"/>
 <result pre=", ColsonP , RaoultDNew insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int. J. Antimicrob."/>
 <result pre="Randomized, Controlled Trial (2020). www.chictr.org.cn/showprojen.aspx?proj=51126 118.GaoJ , TianZ , YangXBreakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
 <result pre=", DruceJD , CattonMG , JansDA , WagstaffKMThe FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitro. Antivir. Res.178,"/>
 <result pre="KorkmazA , ReiterRJ , ManchesterLCEbola virus disease: potential use of" exact="melatonin" post="as a treatment. J. PIneal Res.57(4), 381â€&quot;384 (2014).25262626 134.TanDX"/>
 <result pre="KorkmazA , ReiterRJ , ManchesterLCEbola virus disease: potential use of" exact="melatonin" post="as a treatment. J. Pineal Res.57(4), 381â€&quot;384 (2014).25262626 135.GlowackaI"/>
</results>
